AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration

Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola

Company to release Virtual Investor “Ebola: What This Means” Segment on June 4**th at 9:00 AM ET

OCALA, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced it will release an on-demand video presentation detailing important previously published pre-clinical findings supporting the potential role of its lead drug Ampligen® (rintatolimod) as a prophylactic and/or an early-onset antiviral treatment for Ebola virus disease (EVD).

The Virtual Investor “Ebola: What This Means” Segment will be accessible here on Thursday, June 4, 2026 at 9:00 AM ET.

The announcement comes amid mounting international concern surrounding the rapidly evolving Ebola outbreak involving the Bundibugyo strain (BDBV) currently spreading in parts of Central and East Africa. The World Health Organization (WHO) has declared the outbreak a Public Health Emergency of International Concern (PHEIC), underscoring the growing urgency for effective countermeasures against Ebola, including the current BDBV strain for which there is currently no approved specific treatment or vaccine.

With global public health authorities warning of increased cross-border transmission risk, health care systems and biodefense agencies are actively evaluating scalable antiviral and immune-based therapeutic strategies capable of responding to emerging viral threats.

AIM believes the previously published research conducted at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Biosafety Level 4 laboratories highlights Ampligen’s potential to address this critical unmet medical need.

The peer-reviewed study, titled “Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of action,” reported several important findings that suggest Ampligen’s potential utility as a preventive and/or as an early-intervention antiviral therapeutic, including:

• Ampligen offers 100% protection against Ebola virus with early administration following infection in a mouse model that is otherwise 100% lethal to the mice
• Protection from Ebola in mice was achieved at a dose of 6 mg/kg
• Ampligen is generally well-tolerated in humans at doses of 6 mg/kg
• Ampligen blocks EBOV VP35 viral dsRNA binding and is not a RIG-1-like agonist
• Ampligen acts as a PAMP restricted agonist for direct TLR3 activation

“In vivo pre-clinical analysis performed at the United States Army Medical Research Institute of Infectious Diseases Biosafety Level 4 laboratories suggests that Ampligen has potential as a prophylactic and/or as an early-onset therapeutic in Ebola virus disease,” said AIM CEO Thomas K. Equels.

“The research demonstrated 100% protective survival, compared to 100% mortality in the lethal Ebola virus disease model. We believe these findings are especially relevant given the current Bundibugyo outbreak, which currently lacks an approved targeted therapeutic option. Ampligen’s mechanism of action – as set forth in the peer-reviewed medical journal – may position it as a potentially important countermeasure to help protect health care workers and other vulnerable populations both before and shortly after exposure.”

Mr. Equels added, “As global health authorities intensify efforts to contain the BDBV outbreak and prepare for future viral threats, we believe Ampligen’s previously demonstrated antiviral and immune-modulating properties could attract significant interest from international health organizations, biodefense agencies, and potential strategic partners. We also believe the current outbreak environment may create important opportunities for additional Biosafety Level 4 research access, collaborations and regulatory engagement in the development of Ampligen as a therapeutic for Ebola virus disease.”

Ampligen has previously received Orphan Drug designation for EVD from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The Company’s upcoming presentation will review Ampligen’s mechanism of action, pre-clinical Ebola findings, and potential development pathways in emerging viral disease preparedness and response initiatives.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.